source
- STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle lossA late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.STAT · 1h ago↗ source
- Novartis shareholder urges board overhaul after costly Avidity acquisition setbacksNovartis investor David Samra, managing director at Artisan Partners, told Reuters that the company’s board should be reshaped to improve oversight of its dealmaking activities. He said the board n…